Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development N/A N/A N/A N/A 14.38 million
Income Before Tax N/A N/A N/A N/A -17.22 million
Selling General Administrative N/A N/A N/A N/A 5.73 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -12.54 million
Operating Income N/A N/A N/A N/A -15.64 million
Income Tax Expense 74000 -730000 -3.26 million -3.26 million -1.96 million
Total Revenue N/A N/A N/A N/A 12.08 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 2.04 million
Net Income From Continuing Operations N/A N/A N/A N/A -15.26 million
Net Income Applicable to Common Shares -25.69 million -24.54 million -32.61 million -32.61 million -15.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -81000 -1.87 million -1.87 million -693000 -693000
Change to Liabilities N/A N/A 6.2 million 403000 403000
Total Cash Flow from Investing Activities N/A N/A -1.87 million -693000 -693000
Net Borrowings N/A N/A -406000 -524000 -524000
Total Cash Flow from Financial Activities 6.54 million 88.92 million 88.92 million -65000 -65000
Change to Operating Activities N/A N/A 2.54 million -6.51 million -6.51 million
Change in Cash N/A 67.47 million 67.47 million -20.65 million -20.65 million
Total Cash from Operating Activities N/A N/A -19.58 million -19.9 million -19.9 million
Depreciation N/A N/A N/A 946000 946000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 64000 64000
Other Cash Flow from Financing Activities N/A N/A -4.07 million -47000 -47000
Change to Net Income N/A N/A 1.84 million 463000 463000
Capital Expenditures 81000 841000 841000 693000 693000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities N/A N/A N/A N/A 177.98 million
Total Stockholder Equity N/A N/A N/A N/A 487.81 million
Other Current Liabilities 18.31 million 22.22 million N/A N/A N/A
Total Assets N/A N/A N/A N/A 665.79 million
Common Stock 1.07 billion 1.06 billion 1.05 billion N/A 960.45 million
Other Current Assets N/A N/A N/A 1.05 billion N/A
Retained Earnings -598.99 million -573.3 million -548.76 million -548.76 million -516.15 million
Other Liabilities 21.94 million 23.22 million 30.79 million 30.79 million 35.58 million
Other Assets 3.21 million 3.33 million 3.31 million 3.31 million 3.24 million
Cash N/A N/A N/A N/A 60.08 million
Total Current Liabilities 91.04 million 87.7 million N/A N/A 76.69 million
Other Stockholder Equity 52.19 million 48.8 million 46.63 million 46.63 million 43.51 million
Property, Plant & Equipment 10.41 million 10.33 million 10.27 million 10.27 million 9.44 million
Total Current Assets 90.46 million 115.74 million N/A N/A 69.39 million
Long Term Investments N/A N/A N/A N/A 1.77 million
Net Tangible Assets -62.6 million -42.71 million -32.28 million -32.28 million -94.13 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 59.95 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 28.61 million 27.6 million N/A N/A 19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-03-20100CALL0 00TRUE00
2026-03-20110CALL0 00TRUE00
2026-03-20120CALL0 053.74TRUE00
2026-03-20130CALL0 0360.94TRUE00
2026-03-20140CALL0 0395.06TRUE00
2026-03-20150.4CALL10 046.29FALSE0.40
2026-03-20160CALL0 0247.51FALSE00
2026-03-20170.55CALL0 2142.56FALSE00
2026-03-20180.8CALL0 211435.01FALSE00
2026-03-20190.5CALL0 1090157.79FALSE00
2026-03-20200.3CALL0 480201.81FALSE00
2026-03-20211.15CALL0 5545.08FALSE00
2026-03-20220.3CALL0 5559.82FALSE00
2026-03-20230.15CALL0 6573.56FALSE00
2026-03-20240CALL0 0586.44FALSE00
2026-03-20250.6CALL0 180582.22FALSE00
2026-03-20300CALL0 0650.11FALSE00
2026-03-20350CALL0 0634.73FALSE00
2026-03-20100PUT0 0749.36FALSE00
2026-03-20110PUT0 0658.72FALSE00
2026-03-20120PUT0 0214.49FALSE00
2026-03-20130PUT0 0159.73FALSE00
2026-03-20140PUT0 0241.02FALSE00
2026-03-20151.61PUT45 1150109.26TRUE0.210.15
2026-03-20161.3PUT0 222133.31TRUE00
2026-03-20171.5PUT0 1797.79TRUE00
2026-03-20182.5PUT0 184102.59TRUE00
2026-03-20193PUT0 12129.77TRUE00
2026-03-20203.8PUT0 1138.52TRUE00
2026-03-20210PUT0 0151.74TRUE00
2026-03-20220PUT0 0163.97TRUE00
2026-03-20230PUT0 0175.36TRUE00
2026-03-20240PUT0 0186.03TRUE00
2026-03-20250PUT0 0188.76TRUE00
2026-03-20300PUT0 0230.91TRUE00
2026-03-20350PUT0 0273.19TRUE00
2026-04-1730CALL0 00TRUE00
2026-04-1740CALL0 00TRUE00
2026-04-1750CALL0 00TRUE00
2026-04-1760CALL0 00TRUE00
2026-04-1770CALL0 00TRUE00
2026-04-17810.3CALL0 20TRUE00
2026-04-1799.75CALL0 40TRUE00
2026-04-17105.8CALL0 1920TRUE00
2026-04-17110CALL0 071.13TRUE00
2026-04-17125.62CALL0 25254.25TRUE00
2026-04-17135.1CALL0 19220.98TRUE00
2026-04-17143.6CALL0 82274.03TRUE00
2026-04-17152.32CALL0 58136.25FALSE00
2026-04-17162.36CALL0 352101.01FALSE00
2026-04-17170.5CALL10 28962.49FALSE0.50
2026-04-17181.57CALL0 527160.31FALSE00
2026-04-17191CALL0 761314.1FALSE00
2026-04-17200.92CALL0 1298324.68FALSE00
2026-04-17210.45CALL0 2431159.89FALSE00
2026-04-17250.4CALL0 4402163.32FALSE00
2026-04-17300.24CALL0 462399.09FALSE00
2026-04-17350.2CALL0 1058424.21FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1740PUT0 00FALSE00
2026-04-1750PUT0 00FALSE00
2026-04-1760PUT0 0916.36FALSE00
2026-04-1770PUT0 0728.53FALSE00
2026-04-1780PUT0 0613.17FALSE00
2026-04-1790PUT0 0528.92FALSE00
2026-04-17101.7PUT0 0462.08FALSE00
2026-04-17111.85PUT0 13406.28FALSE00
2026-04-17120.75PUT0 14107.93FALSE00
2026-04-17130.8PUT0 55204.34FALSE00
2026-04-17141.45PUT202 1187.36FALSE1.450
2026-04-17152.25PUT5 13999.7TRUE2.250
2026-04-17162.7PUT6 1990.68TRUE-0.8-0.23
2026-04-17172.12PUT0 5195.6TRUE00
2026-04-17181.8PUT0 13297.87TRUE00
2026-04-17193.7PUT0 30103.45TRUE00
2026-04-17204.1PUT0 2184.01TRUE00
2026-04-17210PUT0 0103.34TRUE00
2026-04-17257.6PUT0 2124.21TRUE00
2026-04-173010.2PUT0 3151.48TRUE00
2026-04-17350PUT0 0168.42TRUE00
2026-07-1730CALL0 00TRUE00
2026-07-1740CALL0 00TRUE00
2026-07-1750CALL0 00TRUE00
2026-07-1760CALL0 00TRUE00
2026-07-1770CALL0 00TRUE00
2026-07-1780CALL0 062.27TRUE00
2026-07-1790CALL0 060.82TRUE00
2026-07-17106.25CALL0 2549.17TRUE00
2026-07-17110CALL0 062.44TRUE00
2026-07-17125.9CALL0 1664.97TRUE00
2026-07-17136.9CALL0 370.73TRUE00
2026-07-17146.3CALL0 471.9TRUE00
2026-07-17155.61CALL0 984.08FALSE00
2026-07-17163.52CALL0 2160.97FALSE00
2026-07-17173.2CALL0 54373.35FALSE00
2026-07-17181.35CALL290 1268.08FALSE1.350
2026-07-17192.05CALL0 1667.25FALSE00
2026-07-17200.96CALL9 7168.73FALSE-0.15-0.14
2026-07-17210.9CALL102 5372.06FALSE0.90
2026-07-17222.75CALL0 10274.33FALSE00
2026-07-17231.25CALL0 49201.49FALSE00
2026-07-17243CALL0 1206.07FALSE00
2026-07-17251CALL0 1723126.15FALSE00
2026-07-17300CALL0 0228.69FALSE00
2026-07-17350CALL0 0243.19FALSE00
2026-07-1730PUT0 00FALSE00
2026-07-1740PUT0 00FALSE00
2026-07-1750PUT0 00FALSE00
2026-07-1760PUT0 0533.35FALSE00
2026-07-1770PUT0 0423.14FALSE00
2026-07-1780PUT0 0356FALSE00
2026-07-1790PUT0 0307.12FALSE00
2026-07-17100PUT0 0159.38FALSE00
2026-07-17111.15PUT3 585.06FALSE1.150
2026-07-17120PUT0 0208.31FALSE00
2026-07-17130PUT0 0101.63FALSE00
2026-07-17142.2PUT0 1160.99FALSE00
2026-07-17152.65PUT0 159.24TRUE00
2026-07-17162.3PUT0 869.91TRUE00
2026-07-17173.8PUT0 2190.32TRUE00
2026-07-17180PUT0 085.56TRUE00
2026-07-17194.1PUT0 181.06TRUE00
2026-07-17200PUT0 085.94TRUE00
2026-07-17210PUT0 087.15TRUE00
2026-07-17220PUT0 082.77TRUE00
2026-07-17230PUT0 082.36TRUE00
2026-07-17240PUT0 084.97TRUE00
2026-07-17250PUT0 089.12TRUE00
2026-07-17300PUT0 098.46TRUE00
2026-07-17350PUT0 0112.43TRUE00
2026-10-1650CALL0 00TRUE00
2026-10-16100CALL0 060.27TRUE00
2026-10-16110CALL0 065.78TRUE00
2026-10-16120CALL0 067.99TRUE00
2026-10-16130CALL0 069.53TRUE00
2026-10-16140CALL0 066.04TRUE00
2026-10-16150CALL0 066.21FALSE00
2026-10-16160CALL0 070.82FALSE00
2026-10-16174.3CALL0 3072.23FALSE00
2026-10-16180CALL0 078.31FALSE00
2026-10-16190CALL0 083.75FALSE00
2026-10-16200CALL0 088.68FALSE00
2026-10-16210CALL0 093.2FALSE00
2026-10-16220CALL0 0151.42FALSE00
2026-10-16250CALL0 0162.13FALSE00
2026-10-16300CALL0 0176.36FALSE00
2026-10-1650PUT0 00FALSE00
2026-10-16100PUT0 0209.71FALSE00
2026-10-16110PUT0 0114.34FALSE00
2026-10-16120PUT0 093.67FALSE00
2026-10-16130PUT0 084.95FALSE00
2026-10-16140PUT0 083.32FALSE00
2026-10-16150PUT0 080.88TRUE00
2026-10-16160PUT0 084.4TRUE00
2026-10-16170PUT0 082.62TRUE00
2026-10-16180PUT0 081.29TRUE00
2026-10-16190PUT0 084.82TRUE00
2026-10-16200PUT0 082.29TRUE00
2026-10-16210PUT0 084.82TRUE00
2026-10-16220PUT0 088.08TRUE00
2026-10-16250PUT0 087.76TRUE00
2026-10-16300PUT0 090.87TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-1559.44CALL1 0123.61TRUE9.440
2027-01-1588.5CALL0 250.23TRUE00
2027-01-15106.9CALL0 26660.05TRUE00
2027-01-15128.74CALL0 1074.63TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15154CALL0 3074.28FALSE00
2027-01-15174.52CALL0 46163.89FALSE00
2027-01-15202.6CALL0 35281.6FALSE00
2027-01-15223.5CALL0 83127.27FALSE00
2027-01-15251.9CALL1 7378.39FALSE1.90
2027-01-15271.55CALL40 49576.47FALSE-0.1-0.06
2027-01-15301.33CALL0 53148.43FALSE00
2027-01-15350CALL0 0157.98FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550.55PUT0 10FALSE00
2027-01-1580PUT0 0236.93FALSE00
2027-01-15103.6PUT50 52135.98FALSE3.60
2027-01-15120PUT0 084.83FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15153PUT0 184.33TRUE00
2027-01-15170PUT0 082.56TRUE00
2027-01-152010.3PUT50 53126.97TRUE10.30
2027-01-15220PUT0 086.83TRUE00
2027-01-15250PUT0 087.43TRUE00
2027-01-15270PUT0 083.23TRUE00
2027-01-15300PUT0 085.37TRUE00
2027-01-15350PUT0 090.12TRUE00
2028-01-21311.4CALL5 00TRUE11.40
2028-01-2150CALL0 051.77TRUE00
2028-01-21811.51CALL0 259.11TRUE00
2028-01-21107.3CALL0 6956.83TRUE00
2028-01-21125.7CALL2 6055.64TRUE-0.52-0.08
2028-01-21154.88CALL94 36783.4FALSE-0.62-0.11
2028-01-21174.4CALL91 133362.44FALSE-0.6-0.12
2028-01-21204.39CALL87 199171.8FALSE0.190.05
2028-01-21223.8CALL61 128269.37FALSE00
2028-01-21253.3CALL81 73569.49FALSE-0.2-0.06
2028-01-21273.16CALL143 106471.38FALSE-0.04-0.01
2028-01-21302.6CALL740 55469.03FALSE-0.3-0.1
2028-01-21352CALL1 89067.6FALSE-0.5-0.2
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 00FALSE00
2028-01-2182.22PUT6 089.89FALSE2.220
2028-01-21102.66PUT1 6577.18FALSE2.660
2028-01-21123.8PUT2 3477.58FALSE3.80
2028-01-21154.75PUT0 2982.04TRUE00
2028-01-21170PUT0 076.55TRUE00
2028-01-21209PUT0 1080.47TRUE00
2028-01-212211PUT0 1079.83TRUE00
2028-01-212512.5PUT0 3081.01TRUE00
2028-01-21270PUT0 078.94TRUE00
2028-01-21300PUT0 078.28TRUE00
2028-01-21350PUT0 079.77TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm